Clinical Trials · NCT01262456
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 395
- Start date
- Feb 2011
- Locations
- 56 sites, United States, Canada
- Primary endpoint
- Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period